I A Zupanets1, S K Shebeko1, O S Popov2, A S Shalamay3. 1. National University of Pharmacy, 27 Pushkinska Str., Kharkiv, 61057, Ukraine. 2. National University of Pharmacy, 27 Pushkinska Str., Kharkiv, 61057, Ukraine. oleksii.s.popov@gmail.com. 3. PJSC SIC "Borshchahivskiy CPP", Kyiv, Ukraine.
Abstract
OBJECTIVE: The aim of the present study was to investigate anti-inflammatory activity of Diclocor in the setting of collagen-induced osteoarthritis in rats in comparison with its active monocomponents-diclofenac sodium and quercetin. METHODS: The study was conducted on the model of collagen-induced osteoarthritis and included measurement of sialic acids, glycoproteins, C-reactive protein, prostaglandin E2, 6-keto-prostaglandin F1α, thromboxane B2, and leukotriene B4. Lastly, morphologic study with morphometry was also performed. RESULTS: Diclocor is superior to quercetin and diclofenac sodium by the degree of pharmacological effect on some of the studied parameters. The differences between the values were statistically significant. CONCLUSION: Diclocor is a promising corrector of inflammatory and destructive joint diseases. Owing to the presence of both diclofenac sodium and quercetin in its composition, Diclocor exhibits a complex mechanism of anti-inflammatory action affecting cyclooxygenase and lipoxygenase ways of arachidonic acid biotransformation.
OBJECTIVE: The aim of the present study was to investigate anti-inflammatory activity of Diclocor in the setting of collagen-induced osteoarthritis in rats in comparison with its active monocomponents-diclofenac sodium and quercetin. METHODS: The study was conducted on the model of collagen-induced osteoarthritis and included measurement of sialic acids, glycoproteins, C-reactive protein, prostaglandin E2, 6-keto-prostaglandin F1α, thromboxane B2, and leukotriene B4. Lastly, morphologic study with morphometry was also performed. RESULTS:Diclocor is superior to quercetin and diclofenac sodium by the degree of pharmacological effect on some of the studied parameters. The differences between the values were statistically significant. CONCLUSION:Diclocor is a promising corrector of inflammatory and destructive joint diseases. Owing to the presence of both diclofenac sodium and quercetin in its composition, Diclocor exhibits a complex mechanism of anti-inflammatory action affecting cyclooxygenase and lipoxygenase ways of arachidonic acid biotransformation.
Authors: Elaine F Remmers; Bina Joe; Marie M Griffiths; David E Dobbins; Svetlana V Dracheva; Akira Hashiramoto; Takefumi Furuya; Jennifer L Salstrom; JianPing Wang; Pércio S Gulko; Grant W Cannon; Ronald L Wilder Journal: Arthritis Rheum Date: 2002-08
Authors: A P Rogerio; A Kanashiro; C Fontanari; E V G da Silva; Y M Lucisano-Valim; E G Soares; L H Faccioli Journal: Inflamm Res Date: 2007-10 Impact factor: 4.575
Authors: Wai Mun Loke; Julie M Proudfoot; Scott Stewart; Allan J McKinley; Paul W Needs; Paul A Kroon; Jonathan M Hodgson; Kevin D Croft Journal: Biochem Pharmacol Date: 2007-11-12 Impact factor: 5.858